Novartis AG
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Novartis AG (NVS), a Swiss multinational pharmaceutical company headquartered in Basel and founded in 1996 through the merger of Ciba-Geigy and Sandoz, develops, manufactures and markets innovative medicines focused on oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases; key products include Kisqali (ribociclib) for breast cancer, Cosentyx (secukinumab) for psoriasis and arthritis, Entresto (sacubitril/valsartan) for heart failure, Kesimpta (ofatumumab) for multiple sclerosis, Pluvicto for prostate cancer, Scemblix (asciminib) for leukemia, Leqvio for cholesterol reduction, Zolgensma for spinal muscular atrophy, and radioligand therapies alongside gene and cell therapies like Kymriah (tisagenlecleucel). The company operates globally with major research hubs in Cambridge, Massachusetts, and expanded facilities in the US including a new San Diego research center planned for 2028-2029 and manufacturing investments totaling over $23 billion across 10 sites to achieve 100% end-to-end US production of key medicines by end-2025; it spun off its generics division Sandoz in October 2023 and Alcon eye care in 2019 to sharpen focus on high-value innovative medicines. Recent strategic moves include the October 2025 $12 billion acquisition of Avidity Biosciences to bolster RNA therapeutics for neuromuscular diseases, completion of Tourmaline Bio acquisition for pipeline enhancement, February 2025 purchase of Anthos Therapeutics for $925 million in cardiovascular assets, April 2025 agreement to acquire Regulus Therapeutics for up to $1.7 billion in microRNA therapies, plus licensing deals with Argo Biopharma, Arvinas, Arrowhead Pharmaceuticals and Dren Bio exceeding $17 billion in potential value to offset patent losses and drive 5-6% compound annual sales growth through 2030.
Company News
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial
Novartis shares down as failed cholesterol drug study increases pipeline pressure
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
RBC backs Oxford BioMedica with 'outperform' rating amid Novartis trial halt
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis could cut about 130 jobs in Basel site relocation
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
Novartis' Remibrutinib Shows Promise in Phase III Trials for Multiple Sclerosis
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping
Stock Futures Look to Start September on a Low Note